Lupin receives USFDA approval for Fosaprepitant for Injection

Lupin has announced that it has received approval for its Fosaprepitant for Injection, 150 mg Single-Dose Vial, from the United States Food and Drug Administration.

Lupin’s Fosaprepitant for Injection, 150 mg Single-Dose Vial, is the generic version of Emend® for Injection, 150 mg Single-Dose Vial, of Merck Sharp & Dohme Corp. (Merck). It is indicated for adults in combination with other antiemetic agents, for the prevention of:

• Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
• Delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Fosaprepitant for Injection, 150 mg Single-Dose Vial, had annual sales of approximately USD 285 million in the US (IQVIA MAT June 2019).